Cargando…

A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized &quo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chorin, E, Topaz, M, Schwartz, A L, Hochstadt, A, Shotan, A, Ashkenazi, I, Kazatsker, M, Nof, E, Beinart, R, Glikson, M, Mazo, A, Milman, A, Banai, S, Rosso, R, Viskin, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206707/
http://dx.doi.org/10.1093/europace/euad122.502
_version_ 1785046288306274304
author Chorin, E
Topaz, M
Schwartz, A L
Hochstadt, A
Shotan, A
Ashkenazi, I
Kazatsker, M
Nof, E
Beinart, R
Glikson, M
Mazo, A
Milman, A
Banai, S
Rosso, R
Viskin, S
author_facet Chorin, E
Topaz, M
Schwartz, A L
Hochstadt, A
Shotan, A
Ashkenazi, I
Kazatsker, M
Nof, E
Beinart, R
Glikson, M
Mazo, A
Milman, A
Banai, S
Rosso, R
Viskin, S
author_sort Chorin, E
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized "pocket infections." OBJECTIVES: We evaluated the efficacy of delivering "Continuous, In-situ-Targeted, ultra-high concentration of Antibiotics" (CITA) into the infected subcutaneous the device-pocket, obviating the need for device/lead-extraction. METHODS: The CITA-Group consisted of 80 patients with pocket infection who were treated with CITA during 2007-2021. Of them, nine patients declined lead-extraction because of prohibitive operative risk, and six patients had questionable indications for extraction. The remaining 65 patients with pocket infection, who were eligible for extraction but opted for CITA treatment, were compared to 81 patients with pocket infection and similar characteristics who underwent device/lead-extraction as primary therapy. RESULTS: Eighty patients with pocket infection were treated with CITA during 2007-2021. CITA was curative in 85% (68/80) patients, who remained free of infection (median follow-up: 3 years, interquartile range 1 – 6.8 years). In the case-control study of CITA vs. device/lead extraction, cure rates were higher after device/lead-extraction than after CITA [96.2%; (78/81) vs. 84.6%; (55/65), p=0.027]. However, rates of serious complications were also higher after extraction [12 (14.8%) vs. 1 (1.5%), p=0.005]. All-cause 1-month and 1-year mortality were similar for CITA and device/lead-extraction (0% vs. 3·7%, p=0·25 and 12·3% vs. 13·6%, p=1·00, respectively). Extraction was avoided in 90·8% (59/65) extraction-eligible patients treated with CITA. CONCLUSIONS: CITA is a safe and effective alternative for patients with pocket infection who are unsuitable or unwilling to undergo extraction. [Figure: see text]
format Online
Article
Text
id pubmed-10206707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102067072023-05-25 A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection Chorin, E Topaz, M Schwartz, A L Hochstadt, A Shotan, A Ashkenazi, I Kazatsker, M Nof, E Beinart, R Glikson, M Mazo, A Milman, A Banai, S Rosso, R Viskin, S Europace 14.5 - Device Complications and Lead Extraction FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Present guidelines endorse complete removal of cardiovascular-implantable electronic devices (pacemakers/defibrillators), including extraction of intracardiac electrodes, not only for systemic infections but also for localized "pocket infections." OBJECTIVES: We evaluated the efficacy of delivering "Continuous, In-situ-Targeted, ultra-high concentration of Antibiotics" (CITA) into the infected subcutaneous the device-pocket, obviating the need for device/lead-extraction. METHODS: The CITA-Group consisted of 80 patients with pocket infection who were treated with CITA during 2007-2021. Of them, nine patients declined lead-extraction because of prohibitive operative risk, and six patients had questionable indications for extraction. The remaining 65 patients with pocket infection, who were eligible for extraction but opted for CITA treatment, were compared to 81 patients with pocket infection and similar characteristics who underwent device/lead-extraction as primary therapy. RESULTS: Eighty patients with pocket infection were treated with CITA during 2007-2021. CITA was curative in 85% (68/80) patients, who remained free of infection (median follow-up: 3 years, interquartile range 1 – 6.8 years). In the case-control study of CITA vs. device/lead extraction, cure rates were higher after device/lead-extraction than after CITA [96.2%; (78/81) vs. 84.6%; (55/65), p=0.027]. However, rates of serious complications were also higher after extraction [12 (14.8%) vs. 1 (1.5%), p=0.005]. All-cause 1-month and 1-year mortality were similar for CITA and device/lead-extraction (0% vs. 3·7%, p=0·25 and 12·3% vs. 13·6%, p=1·00, respectively). Extraction was avoided in 90·8% (59/65) extraction-eligible patients treated with CITA. CONCLUSIONS: CITA is a safe and effective alternative for patients with pocket infection who are unsuitable or unwilling to undergo extraction. [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10206707/ http://dx.doi.org/10.1093/europace/euad122.502 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 14.5 - Device Complications and Lead Extraction
Chorin, E
Topaz, M
Schwartz, A L
Hochstadt, A
Shotan, A
Ashkenazi, I
Kazatsker, M
Nof, E
Beinart, R
Glikson, M
Mazo, A
Milman, A
Banai, S
Rosso, R
Viskin, S
A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title_full A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title_fullStr A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title_full_unstemmed A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title_short A Novel Antibiotic Delivery Approach for Salvage of Cardiovascular-Implantable Electronic Devices with Localized Infection
title_sort novel antibiotic delivery approach for salvage of cardiovascular-implantable electronic devices with localized infection
topic 14.5 - Device Complications and Lead Extraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206707/
http://dx.doi.org/10.1093/europace/euad122.502
work_keys_str_mv AT chorine anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT topazm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT schwartzal anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT hochstadta anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT shotana anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT ashkenazii anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT kazatskerm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT nofe anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT beinartr anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT gliksonm anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT mazoa anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT milmana anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT banais anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT rossor anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT viskins anovelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT chorine novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT topazm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT schwartzal novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT hochstadta novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT shotana novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT ashkenazii novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT kazatskerm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT nofe novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT beinartr novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT gliksonm novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT mazoa novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT milmana novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT banais novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT rossor novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection
AT viskins novelantibioticdeliveryapproachforsalvageofcardiovascularimplantableelectronicdeviceswithlocalizedinfection